# A Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies

Source: https://onco.cc/trials/nct06971523/  
OnCo record `nct06971523` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of CTS3497 in non-Hodgkin lymphoma, run by CytosinLab Therapeutics Co., Ltd., now recruiting.

## Summary

A Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies is a phase 1/2 interventional study registered as NCT06971523 by CytosinLab Therapeutics Co., Ltd., with 224 participants planned, started 2024-12-25 and due to reach its primary completion in 2028-12-31. Interventions recorded: CTS3497.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06971523
- Phase: 1/2
- Setting: A Multi-center, Open-label, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of CTS3497 in Patients With MTAP Deficient Advanced Solid Tumors and Lymphomas
- Sponsor: CytosinLab Therapeutics Co., Ltd.
- Enrolled: 224

## Sources

- ClinicalTrials.gov NCT06971523: https://clinicaltrials.gov/study/NCT06971523

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)

---
JSON: https://onco.cc/api/v1/entities/nct06971523.json